Skip to main content

Want a detailed portfolio tracker?

LYEL
NASDAQ
$12.92

Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Website: https://www.lyell.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Buy
Target: $37.17 (+187.69%)

Market Cap

$333M

Free Cash Flow Yield

-40.41%

Beta (5Y)

1.46

Price Chart

Valuation
Market Cap$333M
P/S11272.00
P/B1.20
Profitability
Total Revenue (TTM)$31K
Gross Profit (TTM)$31K
EBITDA-$246M
Operating Margin-2213050%
EPS-$12.55
Financial Health
Free Cash Flow Yield-40.41%
Growth & Risk
Beta (5Y)1.46
Sharpe Ratio0.73